Millions of people are affected by nonalcoholic steatohepatitis (NASH), which is a serious liver disease. A newly discovered amino acid compound has been found to successfully treat nonalcoholic fatty liver disease in non-human primates, representing a significant step towards the development of th
A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.